- Home
- MHH vs MGNX Comparison
MHH vs MGNX Comparison
Compare MHH & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHH
- MGNX
- Stock Information
- Founded
- MHH 1986
- MGNX 2000
- Country
- MHH United States
- MGNX United States
- Employees
- MHH N/A
- MGNX N/A
- Industry
- MHH Professional Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- MHH Consumer Discretionary
- MGNX Health Care
- Exchange
- MHH Nasdaq
- MGNX Nasdaq
- Market Cap
- MHH 78.2M
- MGNX 87.7M
- IPO Year
- MHH N/A
- MGNX 2013
- Fundamental
- Price
- MHH $7.01
- MGNX $1.46
- Analyst Decision
- MHH
- MGNX Hold
- Analyst Count
- MHH 0
- MGNX 9
- Target Price
- MHH N/A
- MGNX $5.33
- AVG Volume (30 Days)
- MHH 15.4K
- MGNX 2.7M
- Earning Date
- MHH 08-06-2025
- MGNX 08-05-2025
- Dividend Yield
- MHH N/A
- MGNX N/A
- EPS Growth
- MHH N/A
- MGNX N/A
- EPS
- MHH 0.17
- MGNX N/A
- Revenue
- MHH $200,437,000.00
- MGNX $154,050,000.00
- Revenue This Year
- MHH $1.22
- MGNX N/A
- Revenue Next Year
- MHH $5.41
- MGNX N/A
- P/E Ratio
- MHH $40.81
- MGNX N/A
- Revenue Growth
- MHH 3.93
- MGNX 255.31
- 52 Week Low
- MHH $6.20
- MGNX $0.99
- 52 Week High
- MHH $16.00
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- MHH 49.55
- MGNX 52.60
- Support Level
- MHH $6.60
- MGNX $1.19
- Resistance Level
- MHH $7.70
- MGNX $1.41
- Average True Range (ATR)
- MHH 0.47
- MGNX 0.11
- MACD
- MHH 0.09
- MGNX 0.00
- Stochastic Oscillator
- MHH 43.44
- MGNX 67.07
About MHH Mastech Digital Inc
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.